GlassScriptPhysician profile
Reza Elahimehr
NPI 1750677522
$3,561.92
in general payments reported to CMS, 2019-2025
20 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.07 · 2022: $48.90 · 2023: $400 · 2024: $927 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153 · Travel and Lodging: $1,230 · Education: $85.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.08 |
| Travel and Lodging | $1,229.50 |
| Education | $85.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,095.05 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $270.21 | 2023-2024 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $265.68 | 2022-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $212.41 | 2024-2025 | |
| Amgen INC. | $168.77 | 2022-2025 | Tavneos, Krystexxa, Prolia |
| Travere Therapeutics, INC. | $71.77 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $71.35 | 2024-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.74 | 2025 | Jardiance |
| Janssen Biotech, INC. | $55.35 | 2021-2024 | Stelara, Tremfya |
| Mallinckrodt Hospital Products INC. | $54.23 | 2023 | Acthar |
| Linus Health, INC. | $31.34 | 2023 | |
| Novo Nordisk INC | $29.81 | 2024 | Ozempic, Rybelsus |
| Ardelyx, INC. | $29.80 | 2024 | Ibsrela |
| Kyowa Kirin, INC. | $28.33 | 2021 | |
| Aurinia Pharma U.S., INC. | $24.57 | 2024 | Lupkynis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $21.63 | 2025 | Defencath |
| Vifor Pharma, INC. | $20.59 | 2022 | |
| Opko Pharmaceuticals, LLC | $19.83 | 2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $18.66 | 2024 | Velphoro |
| Horizon Therapeutics Plc | $15.80 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Elahimehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.